CAJ | 학술논문

目的：观察伊立替康（CPT-11）联合雷替曲塞二线治疗晚期胃癌的疗效及不良反应。方法对23例一线化疗方案治疗失败或缓解后再进展的晚期胃癌患者进行化疗，方案为伊立替康150 mg·m-290 min静滴D1；雷替曲塞3 mg·m-215 min静滴D1；3周为1个周期，2个周期后评价疗效。治疗期间进行不良反应评估。结果23例均可评价毒副反应和远期疗效，其中22例患者均可评价近期疗效，有效率为54．54％，中位生存期为5个月（95％CI：3．8～6．2月）。常见毒副反应有中性粒细胞减少、贫血、恶性呕吐、血小板减少、迟发性腹泻等。结论伊立替康联合雷替曲塞在晚期胃癌二线治疗中有一定疗效，毒副作用可耐受，值得进一步临床研究。
목적：관찰이립체강（CPT-11）연합뢰체곡새이선치료만기위암적료효급불량반응。방법대23례일선화료방안치료실패혹완해후재진전적만기위암환자진행화료，방안위이립체강150 mg·m-290 min정적D1；뢰체곡새3 mg·m-215 min정적D1；3주위1개주기，2개주기후평개료효。치료기간진행불량반응평고。결과23례균가평개독부반응화원기료효，기중22례환자균가평개근기료효，유효솔위54．54％，중위생존기위5개월（95％CI：3．8～6．2월）。상견독부반응유중성립세포감소、빈혈、악성구토、혈소판감소、지발성복사등。결론이립체강연합뢰체곡새재만기위암이선치료중유일정료효，독부작용가내수，치득진일보림상연구。
Objective To observe the efficacy and toxicity of irinotecan plus raltitrexed as second-line treatment of advanced gastric cancer.Methods Twenty-three patients with advanced gastric cancer received CPT-11(150 mg·m-2 90 min ivgtt)on day 1 and raltitrexed(3 mg·m-2 15 min ivgtt)on day 1.One cycle lasted 21 days.After every two cycles,therapeutic efficacy was evaluated.Ad-verse reactions were assessed during treatment.Results Toxicity and overall survival could be evaluated in 23 patients.Response rate could be evaluated in 22 patients.The efficiency and disease control rate was 54.54%.The median overall survival were 5 months (95%CI:3.8~6.2).Toxicities were mainly neutropenia,anemia,nausea,vomiting,thrombocytopenia and delayed diarrhea.Conclu-sions Irinotecan combined with raltitrexed as second-line chemotherapy for advanced gastric cancer can achieve efficacy with tolerated adverse reactions,which is worthy of wider application.